Regorafenib Post-marketing Surveillance in Japan

Status Completed

Clinical Trial Summary

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

Clinical Trial Description

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy. A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months and 24 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient. ;

Study Design

Related Conditions & MeSH terms

Gastrointestinal Stromal Tumors

Clinical Trial Details

NCT number	NCT01933958
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase
Start date	September 4, 2013
Completion date	October 29, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05385549` - 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk	Phase 2
Recruiting	`NCT05905887` - Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor	Phase 2
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Completed	`NCT01440959` - Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258	Phase 2
Completed	`NCT00718562` - Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib	Phase 2
Completed	`NCT00385203` - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).	Phase 2
Completed	`NCT00137449` - Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor	Phase 2
Completed	`NCT00237172` - Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)	Phase 2
Terminated	`NCT04409223` - Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib	Phase 3
Active, not recruiting	`NCT03556384` - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)	Phase 2
Recruiting	`NCT04106024` - Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial	Phase 2
Completed	`NCT02171286` - The Oncopanel Pilot (TOP) Study	N/A
Completed	`NCT01114087` - Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility	N/A
Recruiting	`NCT05366816` - ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	Phase 2
Recruiting	`NCT03602092` - Observational Registry Data on GIST Patients
Recruiting	`NCT05197933` - Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach	N/A
Completed	`NCT02931929` - MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT	Phase 1/Phase 2
Withdrawn	`NCT05080621` - Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Phase 1/Phase 2
Completed	`NCT02607332` - Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib	Phase 2
Completed	`NCT02638766` - Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST	Phase 2